PriceTargets.com logo

Inovio Pharmaceuticals - INO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $96.00
  • Forecasted Upside: 808.23%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.57 As of 04/26/2024 01:00 AM ET
▲ +0.45 (4.45%)

This chart shows the closing price for INO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inovio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INO

Analyst Price Target is $96.00
▲ +808.23% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Inovio Pharmaceuticals in the last 3 months. The average price target is $96.00, with a high forecast of $144.00 and a low forecast of $48.00. The average price target represents a 808.23% upside from the last price of $10.57.

This chart shows the closing price for INO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in Inovio Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector PerformLow
1/25/2024OppenheimerUpgradeMarket Perform ➝ Outperform$48.00Low
1/4/2024JMP SecuritiesInitiated CoverageMarket Outperform$144.00Low
3/2/2023Royal Bank of CanadaLower TargetSector Perform$432.00 ➝ $288.00Low
11/9/2022Maxim GroupDowngradeBuy ➝ HoldLow
11/1/2022Bank of AmericaDowngradeNeutral ➝ Underperform$288.00Low
8/17/2022Cantor FitzgeraldReiterated RatingNeutralLow
7/19/2022Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$720.00 ➝ $576.00Low
5/11/2022OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/11/2022Cantor FitzgeraldLower Target$864.00 ➝ $432.00High
3/2/2022Royal Bank of CanadaLower TargetSector Perform$864.00 ➝ $720.00High
1/21/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$1,152.00 ➝ $1,440.00High
12/30/2021Jefferies Financial GroupLower TargetHold$1,152.00 ➝ $864.00High
12/15/2021HC WainwrightReiterated RatingHoldHigh
11/1/2021Royal Bank of CanadaLower TargetSector Perform$1,008.00 ➝ $864.00High
9/10/2021Bank of AmericaDowngradeNeutral ➝ Underperform$1,296.00 ➝ $1,152.00High
7/2/2021OppenheimerReiterated RatingBuy$5,040.00N/A
6/24/2021Jefferies Financial GroupInitiated CoverageHold$1,296.00Medium
5/10/2021Piper SandlerLower TargetHold ➝ Neutral$1,008.00 ➝ $864.00High
4/16/2021HC WainwrightReiterated RatingHoldLow
4/16/2021OppenheimerReiterated RatingBuyLow
3/23/2021Bank of AmericaInitiated CoverageNeutral$1,872.00High
2/11/2021OppenheimerInitiated CoverageOutperform$5,040.00Low
1/8/2021BenchmarkLower TargetBuy$3,600.00 ➝ $2,160.00Medium
11/17/2020Roth CapitalDowngradeNeutral ➝ Sell$1,152.00Medium
11/10/2020Roth CapitalUpgradeSell ➝ Neutral$1,152.00High
9/28/2020Roth CapitalLower Target$1,584.00 ➝ $1,152.00High
9/28/2020Maxim GroupUpgradeHold ➝ Buy$2,880.00High
9/28/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$4,464.00 ➝ $1,728.00High
9/9/2020HC WainwrightReiterated RatingHoldHigh
8/11/2020Stifel NicolausLower Target$3,456.00 ➝ $2,304.00Medium
8/11/2020Cantor FitzgeraldLower Target$6,480.00 ➝ $4,464.00Medium
7/1/2020Roth CapitalDowngradeNeutral ➝ Sell$1,584.00High
7/1/2020Maxim GroupDowngradeBuy ➝ Hold$3,456.00High
6/30/2020BenchmarkReiterated RatingBuyHigh
6/29/2020HC WainwrightDowngradeBuy ➝ NeutralMedium
6/26/2020Stifel NicolausDowngradeBuy ➝ Hold$2,736.00 ➝ $3,456.00High
6/23/2020Maxim GroupBoost Target$2,592.00 ➝ $3,456.00High
6/5/2020HC WainwrightReiterated RatingBuy$2,448.00Low
5/21/2020HC WainwrightReiterated RatingBuy$2,448.00Low
5/21/2020BenchmarkInitiated CoverageBuyHigh
5/13/2020Maxim GroupReiterated RatingBuy$2,592.00High
5/12/2020HC WainwrightReiterated RatingBuy$2,448.00High
4/30/2020Roth CapitalDowngradeBuy ➝ Neutral$1,872.00High
4/29/2020Stifel NicolausBoost TargetBuy$1,152.00 ➝ $2,736.00Medium
4/29/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$1,872.00 ➝ $2,448.00High
4/28/2020HC WainwrightReiterated RatingBuy$1,872.00 ➝ $2,448.00Medium
4/17/2020HC WainwrightReiterated RatingBuy$1,872.00High
4/15/2020Cantor FitzgeraldBoost TargetOverweight$1,728.00 ➝ $1,872.00Medium
4/7/2020HC WainwrightReiterated RatingBuyHigh
4/6/2020Royal Bank of CanadaDowngradeHoldHigh
3/27/2020Maxim GroupInitiated CoverageBuy$1,728.00High
3/13/2020Maxim GroupBoost TargetBuy$864.00 ➝ $1,728.00Low
3/13/2020Piper SandlerDowngradeOverweight ➝ Neutral$1,152.00High
3/13/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$1,008.00Low
3/4/2020Stifel NicolausReiterated RatingBuy$1,008.00High
3/3/2020HC WainwrightReiterated RatingBuy$1,872.00High
2/11/2020HC WainwrightReiterated RatingBuy$1,872.00Low
2/4/2020HC WainwrightReiterated RatingBuy$1,872.00Low
1/24/2020HC WainwrightReiterated RatingBuy$1,872.00High
1/23/2020Maxim GroupReiterated RatingBuyHigh
1/23/2020Royal Bank of CanadaReiterated RatingBuy$1,008.00High
1/6/2020Cantor FitzgeraldReiterated RatingOverweightN/A
1/3/2020HC WainwrightReiterated RatingBuy$1,872.00Medium
1/2/2020Piper Sandler CompaniesLower TargetOverweight$1,440.00 ➝ $1,152.00High
12/19/2019Roth CapitalInitiated CoverageBuy$1,872.00High
11/14/2019Maxim GroupReiterated RatingBuyHigh
11/13/2019HC WainwrightReiterated RatingBuy$1,872.00High
9/18/2019HC WainwrightSet TargetBuy$1,872.00Low
9/16/2019CitigroupReiterated RatingBuy$1,008.00 ➝ $576.00Medium
8/11/2019Maxim GroupReiterated RatingBuy$864.00High
7/17/2019Piper Sandler CompaniesLower TargetOverweight$1,728.00 ➝ $1,440.00High
6/11/2019HC WainwrightReiterated RatingBuy$1,872.00High
5/16/2019HC WainwrightInitiated CoverageBuy$1,872.00Medium
5/7/2019HC WainwrightReiterated RatingBuyHigh
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/27/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Inovio Pharmaceuticals logo
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $10.57
Low: $10.09
High: $10.70

50 Day Range

MA: $10.56
Low: $7.66
High: $13.88

52 Week Range

Now: $10.57
Low: $3.89
High: $14.75

Volume

193,321 shs

Average Volume

510,351 shs

Market Capitalization

$247.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Inovio Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Inovio Pharmaceuticals in the last twelve months: JMP Securities, Oppenheimer Holdings Inc., Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for INO.

What is the current price target for Inovio Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Inovio Pharmaceuticals in the last year. Their average twelve-month price target is $96.00, suggesting a possible upside of 808.2%. JMP Securities has the highest price target set, predicting INO will reach $144.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $48.00 for Inovio Pharmaceuticals in the next year.
View the latest price targets for INO.

What is the current consensus analyst rating for Inovio Pharmaceuticals?

Inovio Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for INO.

What other companies compete with Inovio Pharmaceuticals?

Other companies that are similar to Inovio Pharmaceuticals include AVITA Medical, Utah Medical Products, Accuray, AngioDynamics and TriSalus Life Sciences. Learn More about companies similar to Inovio Pharmaceuticals.

How do I contact Inovio Pharmaceuticals' investor relations team?

Inovio Pharmaceuticals' physical mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company's listed phone number is (267) 440-4200 and its investor relations email address is [email protected]. The official website for Inovio Pharmaceuticals is www.inovio.com. Learn More about contacing Inovio Pharmaceuticals investor relations.